We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Multi-Bay Modular Real Time PCR Instrument Enables Rapid Onsite Nucleic Acid Testing

By LabMedica International staff writers
Posted on 02 Nov 2023

A new generation of compact and inexpensive molecular testing platforms features a unique ultra-low-light CMOS sensor technology that enables the detection of infectious or oncology markers, as well as pathogens in the food and environment. More...

Anitoa Systems (Sunnyvale, CA, USA) has launched new 96-well multi-bay modular real-time PCR (qPCR) instruments in its Maverick line of qPCR products. Anitoa's Maverick multi-bay modular qPCR instrument MQx96 is the company’s first larger format qPCR instrument that comes with multiple independently operable modules. The MQx96 and MQx48 instruments are available in 96 (6X16) and 48 (3X16) well formats, and feature 6X or 3X 16-well qPCR modules, both of which can be independently controlled using a unified software interface. MQx96 is ideal for laboratories that are required to run small sample batches continuously in a pipelined manner.

Maverick qPCR instruments feature technological innovations, including a unique proprietary low-light complementary metal-oxide-semiconductor (CMOS) 4-channel fluorescence optics system that enables rapid and highly multiplexed DNA detection. Additionally, Maverick qPCR instruments are easy to use and do not need calibration, thanks to their solid-state construction. Apart from their operational flexibility, Anitoa's MQ96 (and MQ48) are modular systems with each reaction chamber independently heated and cooled. This enables the instruments to achieve a 30-40% faster reaction time compared to traditional large-block qPCR systems.

"We are excited to offer laboratories worldwide a modular solution for rapid and pipelined nucleic acid tests to help combat diseases by detecting pathogens in human, as well as our food and environment," said Dr. Zhimin Ding, CEO of Anitoa Systems. "We believe our multi-bay modular qPCR instruments and the integrated software offer features that meet the needs of labs seeking higher throughput testing while being extremely flexible."

Related Links:
Anitoa Systems


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
POC Immunoassay Analyzer
Procise DX
Manual Pipetting Aid
Pipette Controllers macro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A large, international study led by City of Hope found that the new, investigational liquid biopsy, called PANXEON, was highly sensitive in detecting stage 1 and 2 pancreatic cancer and had a low rate of false positives. The test was also able to identify high-grade dysplasia, a precancerous condition of the pancreas, potentially enabling intervention before cancer develops. (Photo courtesy of City of Hope)

Multi-Biomarker Blood Test Shows Promise for Early Pancreatic Cancer Detection

Pancreatic cancer has the lowest survival rates of any cancer, with only 14% of patients alive five years after diagnosis. The disease is typically discovered after it has spread, and an estimated 90%... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Pathology

view channel
image Credit: iStock

Tumor Budding Grading May Predict Chemotherapy Benefit in Resected Lung Squamous Cancer

Outcomes after resection for lung squamous cell carcinoma (SqCC) vary substantially, and the uneven benefit of adjuvant chemotherapy complicates postsurgical treatment decisions. Pathologic markers that... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.